Trial intelligence / Profile preview

Phase 3 randomized trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL/SLL

2018-001366-42Phase 3Completed

Sponsor

BeiGene

Start

Oct 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1